BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.

The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.

To view the full press release, visit https://ibn.fm/BqhFS

About VERAXA Biotech AG (NASDAQ: VRXA)

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BillionDollarClub

BillionDollarClub (“BDC”) is a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled recognition and brand awareness.

BDC is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BillionDollarClub, text “Billion” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer

BillionDollarClub
Austin, Texas
www.BillionDollarClub.com
512.354.7000 Office
Editor@BillionDollarClub.com

BillionDollarClub is powered by IBN

Lacey@GCS

Share
Published by
Lacey@GCS

Recent Posts

BillionDollarBreaks – Forward Industries Inc. (NASDAQ: FWDI) Building SOL-Focused Platform with Active On-Chain Strategy

Forward Industries (NASDAQ: FWDI) is building a Solana-focused treasury platform designed to generate value through active…

7 hours ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures 

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with…

2 days ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after…

2 days ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer,…

6 days ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the…

1 week ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support…

2 weeks ago